PsyBio Therapeutics Corp (CVE:PSYB) announced it has retained investor relations firm Kanan Corbin Schupak & Aronow Inc (KCSA Strategic Communications) to raise its profile in the financial community.
“PsyBio has selected KCSA to enhance its visibility and profile in the financial community, as the company continues to execute on its strategies,” it said in a statement.
Toronto-based PsyBio develops novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders.
READ: PsyBio Therapeutics appoints Dr Michael Spigarelli as chief medical officer to lead ongoing development of its drug discovery platform technology
KCSA, a New York-based communications firm, specializes in public relations, shareholder communications and social media, with expertise in financial and professional services, technology, healthcare, digital media, cannabis and energy.
Under the terms of the engagement, KCSA will assist PsyBio in engaging with current and potential investors and work closely with the company to develop and deploy a comprehensive capital markets strategy.
Activities will include providing an investor relations program catering to the financial community, shareholders, and investors, PsyBio told shareholders.
KCSA will be paid a monthly fee of US$8,500 and will not receive any securities as compensation.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas